Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials

P Van Damme, P McIntyre, E Grimprel, S Kuriyakose… - Vaccine, 2011 - Elsevier
BACKGROUND: Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after …

M Kovac, L Kostanyan, N Mesaros… - Human Vaccines & …, 2018 - Taylor & Francis
Pertussis is a highly contagious disease, for which periodic peaks in incidence and an
increasing number of outbreaks have been observed over the last decades. The reduced …

Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®) A Guide to Its Use as a Single-Dose Booster Immunization …

LJ Scott, PL McCormack - BioDrugs, 2013 - Springer
Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Boostrix™) A Review of its Use as a Single-Dose Booster Immunization

JE Frampton, GM Keating - BioDrugs, 2006 - Springer
Reduced-antigen, combined diphtheria, tetanus, and acellular pertactin-containing pertussis
vaccine (dTpa; Boostrix™) contains reduced quantities of the same toxoids/antigens found …

[HTML][HTML] A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria …

R Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - Elsevier
Aim To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …

Reduced-Antigen, Combined Diphtheria, Tetanus and Acellular Pertussis Vaccine, Adsorbed (Boostrix®) A Review of its Properties and Use as a Single-Dose Booster …

PL McCormack - Drugs, 2012 - Springer
Reduced-antigen, combined diphtheria, tetanus and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix™ …

F Zhu, S Zhang, Q Hou, Y Zhang, Y Xu, X Ma… - Human …, 2010 - Taylor & Francis
Pertussis continues to circulate in Chinese communities and older children, adolescents and
adults are sources of infection for unprotected infants. Two studies conducted in Jiangsu …

[HTML][HTML] Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular …

A Tomovici, L Barreto, P Zickler, W Meekison, F Noya… - Vaccine, 2012 - Elsevier
Persistence of antibodies after a single dose of Tdap vaccine (tetanus, diphtheria, and 5-
component acellular pertussis vaccine) was evaluated in a follow-up study of adolescents …

A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) …

B Thierry-Carstensen, K Jordan, HH Uhlving, T Dalby… - Vaccine, 2012 - Elsevier
BACKGROUND: Increasing incidence of pertussis in adolescents and adults has stimulated
the development of safe and immunogenic acellular pertussis vaccines for booster …

Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine

W Weston, M Messier, LR Friedland, X Wu, B Howe - Vaccine, 2011 - Elsevier
The duration of protection after vaccination with reduced antigen content diphtheria, tetanus
and acellular pertussis vaccines (Tdap) is not known. Long-term post-vaccination …